0.22% -16.29

Flexion Therapeutics, Inc. (FLXN)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Flexion Therapeutics, Inc. Stock (FLXN) Company Profile

Flexion Therapeutics, Inc.

Healthcare (1108)

781-305-7777

10 Mall Road, Suite 301, Burlington

최신 SEC 제출 서류

FLXN's Discussions on Twitter

Compare FLXN vs TAK, ZTS, HLN, TEVA, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
FLXN Flexion Therapeutics, Inc.	25.43	0	0	0	0	0.00
TAK Takeda Pharmaceutical Co Adr	18.08	58.26B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.93	54.44B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.61	48.41B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.28	39.33B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	498.65	22.12B	3.13B	1.27B	1.12B	26.39

Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-04-26	재개	Credit Suisse	Outperform
2021-04-07	재개	RBC Capital Mkts	Outperform
2020-08-20	개시	Goldman	Neutral
2020-07-31	개시	Oppenheimer	Outperform
2020-07-29	개시	Credit Suisse	Outperform
2020-06-25	개시	H.C. Wainwright	Buy
2020-05-27	개시	Guggenheim	Buy
2019-12-27	재확인	The Benchmark Company	Buy
2019-12-05	개시	Craig Hallum	Buy
2019-11-25	개시	BTIG Research	Buy
2019-05-09	업그레이드	The Benchmark Company	Hold → Buy
2019-01-04	재확인	Needham	Buy
2019-01-04	다운그레이드	The Benchmark Company	Buy → Hold
2018-06-28	개시	The Benchmark Company	Buy
2017-10-09	재확인	Needham	Buy
2017-08-24	개시	Northland Capital	Outperform
2016-12-22	개시	Raymond James	Strong Buy
2016-09-06	재개	Lake Street	Buy
2016-07-21	개시	Lake Street	Buy
2016-05-03	재개	Wells Fargo	Outperform
2015-11-04	개시	Cantor Fitzgerald	Buy
2015-09-09	재확인	Needham	Buy

Flexion Therapeutics, Inc. 주식(FLXN)의 최신 뉴스

Flexion Therapeutics, Inc. (FLXN) 재무 분석

Flexion Therapeutics, Inc. (FLXN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Flexion Therapeutics, Inc. (FLXN)

Flexion Therapeutics, Inc. Stock (FLXN) Company Profile

Compare FLXN vs TAK, ZTS, HLN, TEVA, UTHR

Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades

Flexion Therapeutics, Inc. 주식(FLXN)의 최신 뉴스

Joint Pain Injections Market Overview and Leading Players: - openPR.com

PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz

Flexion Therapeutics, Inc.Common Stock (NQ: FLXN - FinancialContent

Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN

Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN

Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN

Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research

Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research

Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail

Musculoskeletal Pain Treatment Market Size (7MM) is expected to grow at a significant CAGR by 2034, estimates DelveInsight - The Globe and Mail

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - pharmiweb.com

Musculoskeletal Pain Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - openPR.com

Osteoarthritis Gene Therapy Market Research Report 2025 - InsightAce Analytic

Knee Osteoarthritis Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight - The Globe and Mail

Knee Osteoarthritis Pipeline Drugs Insights Report 2025: - openPR.com

Swollen Knee Treatment Market Expands as Demand for Non-Invasive Therapies Accelerates Globally - newstrail.com

Cipher Mining Inc.Common Stock (NQ: CIFR - FinancialContent

Knee osteoarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics - Barchart.com

Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail

Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma

Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us

High Costs of Knee Osteoarthritis Treatment - Market.us

Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research

Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au

Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire

Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire

Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire

Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire

From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -

Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic

Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire

Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma

Madison Topic FLEXION THERAPEUTICS, INC. | News, Weather, Sports, Breaking News - WMSN

Osteoarthritis Injectables Market Size & Share Report, 2030 - Grand View Research

U.S. Osteoarthritis Injectables Market | Industry Report, 2030 - Grand View Research

Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire

Is Osteoarthritis Cure — ARPA-H NITRO — Rocket Fuel Or TNT? - Clinical Leader

Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look OutTechfields, Centrexion, Biosplice, Ampio, Paradigm, Grünenthal, Naturecell, MiMedx, TissueTech, Organogenesis - Yahoo Finance

Joint Pain Injections Market Strategic Market Study 2033 - SkyQuest Technology Consulting

Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic - PR Newswire

Global Joint Pain Injections Market Size & Share Revenue Is - GlobeNewswire

Osteoarthritis Therapeutics Market to Register a Steady CAGR of 8.70% Between 20222030 - Digital Journal

Versant Development Fund Iii, L.p. Net Worth (2025) - GuruFocus

Utpal Koppikar named Alphabet health firm Verily CFO - The American Bazaar

Indian American Utpal Koppikar Named CFO of Alphabet Precision Health Company Verily - American Kahani

Verily Appoints Utpal Koppikar as Chief Financial Officer - FinancialContent

Flexion Therapeutics, Inc. (FLXN) 재무 분석

매출

순이익

현금흐름

주당 순 이익

FLXN과 유사한 종목